NCT05426005View on ClinicalTrials.gov

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2027

Conditions
Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Interventions
DRUG

Cadonilimab

Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years

Trial Locations (1)

510655

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER